Lab closures 2019

We offer seven-business-day turnaround for all tests, and a three-business-day rush turnaround option for most tests, except microbiology testing. Our lab is only closed on the following statutory holidays.

Good Friday
Friday, April 19
Easter Monday
Monday, April 22
Victoria Day
Monday, May 20
Canada Day
Monday July 1
B.C. Day
Monday August 5
Labour Day
Monday September 2
Thanksgiving Day
Monday October 14
Remembrance Day
Monday November 11
Christmas Day
Wednesday December 25
Boxing Day
Thursday, December 26
  • Turnaround time calculator

    Expect results by

    Expect results by

    We would need samples by 1pm on

    We would need samples by 1pm on

    With rush option, expect results by

    With rush option, we would need samples by

    Due to the holiday, turnaround times might seem longer than expected. Please get in touch for more information.

    Turnaround time calculator dates provided are estimates only

  • Turnaround times explained

    Standard turnaround is 7 business days

    Rush turnaround is 3 business days, except for microbiology, which can’t be rushed

    Even if microbiology is required, a rush option is still available for all other tests

    Microbiology tests start on the first Monday or Wednesday after receiving your samples

    Samples have to arrive before 1pm PST on a business day

    Turnaround time calculator dates provided are estimates only

    Once we received your samples, we’ll confirm by email when you can expect your results

  • How to submit a sample

    New clients
    Please contact us. We need to register you as a client before you can submit any samples.

    Registered clients

    1. Download the latest Chain of Custody (COC) form.
    2. Email your completed form to samples@anandia.ca for review.
    3. Once your COC has been approved, send it together with your samples to:
      Anandia, Testing Division
      322-2259 Lower Mall
      Vancouver, BC V6Y 1Z4
    4. You will receive an email confirmation that your package has been received, which will include the date your results can be expected.
  • Required sample amounts

    Package testing: 60 g (flower) or 60 mL (oil)

    Potency: 10g (flower) or 5mL (oil)

    Cannabinoid profiling: 10g (flower) or 5mL (oil)

    Heavy metal or total metal: 3g (flower) or 1mL (oil)

    Aflatoxin analysis: 3g (flower) or 1mL (oil)

    Ochratoxin analysis: 3g (flower) or 1mL (oil)

    Loss on drying: 3g (flower)

    Terpene profiling: 10g (flower) or 1mL (oil)

    Residual solvents: 1mL (oil)

    Pesticide analysis (96 Analytes): 3g (flower) or 2mL (oil)

    Microbiology (all required tests): 40g (flower) or 40mL (oil)

    TAMC: 10g (flower) or 10mL (oil)

    TYMC: 10g (flower) or 10mL (oil)

    BTGN: 1g (flower) or 1mL (oil)

    E. coli: 1g (flower) or 1mL (oil)

    Salmonella: 25g (flower) or 25mL (oil)

    S. aureus: 1g (flower) or 1mL (oil)

    P. aeruginosa: 1g (flower) or 1mL (oil)

Aurora Bolsters Anandia’s Testing Capabilities Through Acquisition of Chemi Pharmaceutical

Supporting the Growth and Expansion of Anandia’s Independent Cannabis Testing Capabilities

Edmonton, AB – April 25, 2019 – Aurora Cannabis Inc. (“Aurora” or the “Company”) (NYSE: ACB) (TSX: ACB) (Frankfurt: 21P; WKN: A1C4WM) announced today that the company has signed a binding share purchase agreement whereby Aurora has acquired all of the issued and outstanding common shares of privately-held Chemi Pharmaceutical Inc, (“Chemi”), an Ontario-based laboratory specialized in providing high quality analytics services to the pharmaceutical and cannabis industries, in a cash and share transaction (the “Transaction”) comprised of an undisclosed cash payment and share consideration of 83,299 shares paid on closing and 41,649 payable upon achievement of certain Chemi milestones.

Strategic Rationale

Chemi has a Health Canada Drug Establishment Licence enabling them to perform certified GMP compliant quality control analytical testing. In addition, Chemi has received US FDA accreditation for their facility, which is the gold standard for global pharmaceutical testing. Acquiring Chemi with their Drug Establishment Licence provides a critical prerequisite for applying for a Cannabis Drug Licence, which is required for the development of cannabis therapies within the global medical cannabis market.

Strategically located adjacent to Pearson Airport in Mississauga, Ontario, Chemi provides specialized cannabis testing across a broad set of parameters, including cannabinoid and terpene content. Chemi will be integrated into the Company’s wholly owned subsidiary, Anandia Laboratories Inc. (“Anandia”), expanding Anandia’s leading analytics capabilities to meet client demand and diversifying its specialized testing services for both the medical and the upcoming edible and derivatives markets.

Following the acquisition of Anandia in August 2018, Aurora integrated Anandia’s plant science operations into the Company’s broader science team, enabling Anandia to maintain independence as an analytical service provider, with its operations run at arm’s length to ensure client confidentiality.

As the Canadian cannabis industry matures, the cultivation and processing operations of licensed producers, including Aurora, have developed rapidly to meet the growing demand from medical patients and consumers alike. Expanding Anandia’s analytical testing footprint will enable it to service a broader base of domestic and international clients while ensuring continued timelines and quality of its testing services for existing clients.

Management Commentary 

“The acquisition of Chemi will enable Anandia to extend our best-in-class testing services to a broader group of licensed producers and scale alongside our current client base while providing the scientific capabilities to establish an early mover advantage in the upcoming cannabis edibles testing market,” said John Coleman, President of Anandia. “We look forward to integrating the Chemi team into our operations and working together to deliver the greatest scientific integrity to our clients.”

Mariana Stavrikov, General Manager of Chemi, added, “Chemi has been servicing the pharmaceutical, natural health product, cosmetic and veterinary industries for the last 20 years. As a trusted partner to a number of licensed producers, we are thrilled to join the Anandia team and expand our infrastructure and support to accommodate the incredible opportunity ahead in the cannabis industry.”

Terms of the Transaction

Aurora has purchased 100% of the issued and outstanding shares of Chemi for a combination of cash and common shares of Aurora.

About Aurora

 Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 625,000 kg per annum and sales and operations in 24 countries across five continents, Aurora is one of the world’s largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high-quality product at low cost. Intended to be replicable and scalable globally, our production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs. Each of Aurora’s facilities is built to meet EU GMP standards, and its first production facility, the recently acquired MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland have achieved this level of certification.

In addition to the Company’s rapid organic growth and strong execution on strategic M&A, which to date includes 15 wholly owned subsidiary companies – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia, HotHouse Consulting, MED Colombia, Agropro, Borela, and ICC Labs – Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc. (private), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), Alcanna Inc. (TSX: CLIQ) and High Tide Inc. (CSE: HITI).

Aurora’s Common Shares trade on the TSX and NYSE under the symbol “ACB”, and are a constituent of the S&P/TSX Composite Index.

For more information about Aurora, please visit our investor website, investor.auroramj.com

Neither the TSX, NYSE nor their Regulation Services Provider (as that term is defined in the policies of the TSX and NYSE) accepts responsibility for the adequacy or accuracy of this release.

Terry Booth, CEO
Aurora Cannabis Inc.

 

Further information

For Media: 

Heather MacGregor
(416) 509-5416
heather.macgregor@auroramj.com

For Investors:

Marc Lakmaaker
(647) 269-5523
marc.lakmaaker@auroramj.com

Rob Kelly
(647) 331-7228
rob.kelly@auroramj.com

U.S. Investors:

Phil Carlson / Elizabeth Barker
KCSA Strategic Communications
(212) 896-1233 / (212) 896-1203
pcarlson@kcsa.com / ebarker@kcsa.com

 

Forward-Looking Statements

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward looking statements made in this release include: (i) statements regarding expanding Anandia’s capacity, (ii) establishing an early mover advantage in the upcoming cannabis edibles market; (iii) statements regarding the rapid growth of cannabis testing markets. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Certain of the assumptions relied upon include that the infrastructure at Chemi will be expanded. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Emerald Badges

The Emerald Test™ is an Inter-Laboratory Comparison and Proficiency Test (ILC/PT) program for cannabis testing labs. Proficiency test samples are manufactured by an ISO 17043 accredited PT provider. Results are submitted through an electronic data portal and data analysis is provided by the sample manufacturer with software designed to meet the requirements of ISO 13528:2015.

Every path to success is tested

Please confirm your age and province.

The results are in

In , you must be at least years old to proceed.